Do analysts prefer SNYR or HEPA?

Synergy CHC presently has a consensus target price of $6.25, suggesting a potential upside of 3,254.80%. Given Synergy CHC's stronger consensus rating and higher possible upside, equities research analysts plainly believe Synergy CHC is more favorable than Hepion Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer HEPA or CASI?

CASI Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Hepion Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate HEPA or VRAX?

Virax Biolabs Group has a consensus price target of $25.00, suggesting a potential upside of 559.63%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts plainly believe Virax Biolabs Group is more favorable than Hepion Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, HEPA or VRAX?

Virax Biolabs Group has higher revenue and earnings than Hepion Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A Virax Biolabs Group $10K 303.20 -$5.02M N/A N/A

Is HEPA or VRAX more profitable?

Virax Biolabs Group's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hepion Pharmaceuticals N/A -812.56% -207.31% Virax Biolabs Group N/A N/A N/A

Do analysts prefer ARTL or HEPA?

Artelo Biosciences currently has a consensus price target of $54.00, indicating a potential upside of 4,595.65%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Artelo Biosciences is more favorable than Hepion Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, ARTL or HEPA?

Artelo Biosciences is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artelo Biosciences N/A N/A -$12.88M -$32.74 N/A Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A

Is ARTL or HEPA more profitable?

Hepion Pharmaceuticals' return on equity of -812.56% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Artelo Biosciences N/A -1,600.12% -224.62% Hepion Pharmaceuticals N/A -812.56% -207.31%

Do analysts recommend SHPH or HEPA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, SHPH or HEPA?

Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Shuttle Pharmaceuticals N/A N/A -$11.72M -$47.70 N/A Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A

Is SHPH or HEPA more profitable?

Shuttle Pharmaceuticals' return on equity of -408.34% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Shuttle Pharmaceuticals N/A -408.34% -138.15% Hepion Pharmaceuticals N/A -812.56% -207.31%

Hepion Pharmaceuticals (HEPA) Competitors

$0.06 +0.01 (+9.91%)

As of 07/17/2026 03:44 PM Eastern

Compare

HEPA vs. SNYR, CASI, VRAX, ARTL, and SHPH

Should you buy Hepion Pharmaceuticals stock or one of its competitors? MarketBeat compares Hepion Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hepion Pharmaceuticals include Synergy CHC (SNYR), CASI Pharmaceuticals (CASI), Virax Biolabs Group (VRAX), Artelo Biosciences (ARTL), and Shuttle Pharmaceuticals (SHPH). These companies are all part of the "pharmaceutical products" industry.

How does Hepion Pharmaceuticals compare to Synergy CHC?

Synergy CHC (NASDAQ:SNYR) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

Hepion Pharmaceuticals has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synergy CHC	-60.02%	N/A	-30.30%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

In the previous week, Synergy CHC had 1 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 1 mentions for Synergy CHC and 0 mentions for Hepion Pharmaceuticals. Synergy CHC's average media sentiment score of 0.29 beat Hepion Pharmaceuticals' score of 0.00 indicating that Synergy CHC is being referred to more favorably in the media.

Company	Overall Sentiment
Synergy CHC	Neutral
Hepion Pharmaceuticals	Neutral

17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 32.9% of Synergy CHC shares are held by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Synergy CHC presently has a consensus target price of $6.25, suggesting a potential upside of 3,254.80%. Given Synergy CHC's stronger consensus rating and higher possible upside, equities research analysts plainly believe Synergy CHC is more favorable than Hepion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synergy CHC	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Synergy CHC has a beta of -0.14, suggesting that its share price is 114% less volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

Synergy CHC has higher revenue and earnings than Hepion Pharmaceuticals. Synergy CHC is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synergy CHC	$30.38M	0.09	-$12.34M	-$1.40	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

Summary

Synergy CHC beats Hepion Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to CASI Pharmaceuticals?

Hepion Pharmaceuticals (NASDAQ:HEPA) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Hepion Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

CASI Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Hepion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CASI Pharmaceuticals has higher revenue and earnings than Hepion Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Hepion Pharmaceuticals' average media sentiment score of 0.00 equaled CASI Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Hepion Pharmaceuticals	Neutral
CASI Pharmaceuticals	Neutral

Hepion Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

Summary

CASI Pharmaceuticals beats Hepion Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Virax Biolabs Group?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Hepion Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

Virax Biolabs Group has higher revenue and earnings than Hepion Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A
Virax Biolabs Group	$10K	303.20	-$5.02M	N/A	N/A

In the previous week, Virax Biolabs Group had 4 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 4 mentions for Virax Biolabs Group and 0 mentions for Hepion Pharmaceuticals. Virax Biolabs Group's average media sentiment score of 0.33 beat Hepion Pharmaceuticals' score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Hepion Pharmaceuticals	Neutral
Virax Biolabs Group	Neutral

Virax Biolabs Group's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
Virax Biolabs Group	N/A	N/A	N/A

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Virax Biolabs Group has a consensus price target of $25.00, suggesting a potential upside of 559.63%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts plainly believe Virax Biolabs Group is more favorable than Hepion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Virax Biolabs Group beats Hepion Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Artelo Biosciences?

Artelo Biosciences (NASDAQ:ARTL) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Hepion Pharmaceuticals' return on equity of -812.56% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-1,600.12%	-224.62%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

Artelo Biosciences currently has a consensus price target of $54.00, indicating a potential upside of 4,595.65%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Artelo Biosciences is more favorable than Hepion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Artelo Biosciences is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 3.2% of Artelo Biosciences shares are held by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Artelo Biosciences has a beta of -0.11, meaning that its share price is 111% less volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

In the previous week, Artelo Biosciences had 5 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 5 mentions for Artelo Biosciences and 0 mentions for Hepion Pharmaceuticals. Artelo Biosciences' average media sentiment score of 0.29 beat Hepion Pharmaceuticals' score of 0.00 indicating that Artelo Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Artelo Biosciences	Neutral
Hepion Pharmaceuticals	Neutral

Summary

Artelo Biosciences beats Hepion Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Shuttle Pharmaceuticals?

Shuttle Pharmaceuticals (NASDAQ:SHPH) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Shuttle Pharmaceuticals' return on equity of -408.34% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$47.70	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

Shuttle Pharmaceuticals has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Shuttle Pharmaceuticals had 6 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 6 mentions for Shuttle Pharmaceuticals and 0 mentions for Hepion Pharmaceuticals. Shuttle Pharmaceuticals' average media sentiment score of 0.89 beat Hepion Pharmaceuticals' score of 0.00 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Shuttle Pharmaceuticals	Positive
Hepion Pharmaceuticals	Neutral

Summary

Shuttle Pharmaceuticals beats Hepion Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

Get Hepion Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HEPA vs. The Competition

Export

Metric	Hepion Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$698K	$764.99M	$6.89B	$12.43B
Dividend Yield	N/A	4.84%	2.67%	8.84%
P/E Ratio	-0.01	1.50	27.14	23.89
Price / Sales	N/A	114.58	524.02	91.05
Price / Cash	N/A	20.06	51.46	60.07
Price / Book	0.05	8.61	10.69	6.18
Net Income	-$48.93M	-$3.14M	$3.59B	$331.73M
7 Day Performance	N/A	-3.42%	-2.17%	-2.09%
1 Month Performance	N/A	-2.40%	1.63%	-2.19%
1 Year Performance	N/A	31.93%	25.56%	17.20%

Hepion Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HEPA Hepion Pharmaceuticals	N/A	$0.06 +9.9%	N/A	+40.2%	$698K	N/A	N/A	20	Gap Up
SNYR Synergy CHC	2.1486 of 5 stars	$0.20 -3.3%	$6.25 +3,093.7%	-94.9%	$2.95M	$27.70M	N/A	40	Short Interest Increase Gap Down
CASI CASI Pharmaceuticals	N/A	$0.21 flat	$4.00 +1,827.7%	N/A	$2.55M	$26.85M	N/A	180
VRAX Virax Biolabs Group	2.6843 of 5 stars	$3.18 +4.6%	$25.00 +686.2%	-83.5%	$2.54M	$10K	N/A	5	News Coverage Positive News
ARTL Artelo Biosciences	1.4015 of 5 stars	$1.00 -0.9%	$54.00 +5,320.1%	-97.6%	$2.32M	N/A	N/A	5	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HEPA) was last updated on 7/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hepion Pharmaceuticals (HEPA) Competitors

HEPA vs. SNYR, CASI, VRAX, ARTL, and SHPH

How does Hepion Pharmaceuticals compare to Synergy CHC?

Summary

How does Hepion Pharmaceuticals compare to CASI Pharmaceuticals?

Summary

How does Hepion Pharmaceuticals compare to Virax Biolabs Group?

Summary

How does Hepion Pharmaceuticals compare to Artelo Biosciences?

Summary

How does Hepion Pharmaceuticals compare to Shuttle Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEPA vs. The Competition

Hepion Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hepion Pharmaceuticals (HEPA) Competitors

HEPA vs. SNYR, CASI, VRAX, ARTL, and SHPH

How does Hepion Pharmaceuticals compare to Synergy CHC?

Is SNYR or HEPA more profitable?

Does the media favor SNYR or HEPA?

Do insiders & institutionals have more ownership in SNYR or HEPA?

Do analysts prefer SNYR or HEPA?

Which has more risk and volatility, SNYR or HEPA?

Which has stronger valuation & earnings, SNYR or HEPA?

Summary

How does Hepion Pharmaceuticals compare to CASI Pharmaceuticals?

Which has more risk & volatility, HEPA or CASI?

Do analysts prefer HEPA or CASI?

Which has stronger earnings & valuation, HEPA or CASI?

Do institutionals and insiders have more ownership in HEPA or CASI?

Does the media refer more to HEPA or CASI?

Is HEPA or CASI more profitable?

Summary

How does Hepion Pharmaceuticals compare to Virax Biolabs Group?

Which has more volatility & risk, HEPA or VRAX?

Which has preferable earnings & valuation, HEPA or VRAX?

Does the media favor HEPA or VRAX?

Is HEPA or VRAX more profitable?

Do insiders & institutionals have more ownership in HEPA or VRAX?

Do analysts rate HEPA or VRAX?

Summary

How does Hepion Pharmaceuticals compare to Artelo Biosciences?

Is ARTL or HEPA more profitable?

Do analysts prefer ARTL or HEPA?

Which has stronger earnings & valuation, ARTL or HEPA?

Do institutionals and insiders believe in ARTL or HEPA?

Which has more risk & volatility, ARTL or HEPA?

Does the media prefer ARTL or HEPA?

Summary

How does Hepion Pharmaceuticals compare to Shuttle Pharmaceuticals?

Is SHPH or HEPA more profitable?

Which has higher valuation & earnings, SHPH or HEPA?

Which has more risk and volatility, SHPH or HEPA?

Do analysts recommend SHPH or HEPA?

Do insiders and institutionals believe in SHPH or HEPA?

Does the media prefer SHPH or HEPA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEPA vs. The Competition

Hepion Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools